PL1877098T3 - Koniugaty estru alfa-aminokwasu z lekiem ulegające hydrolizie z udziałem karboksyloesterazy - Google Patents

Koniugaty estru alfa-aminokwasu z lekiem ulegające hydrolizie z udziałem karboksyloesterazy

Info

Publication number
PL1877098T3
PL1877098T3 PL06727008T PL06727008T PL1877098T3 PL 1877098 T3 PL1877098 T3 PL 1877098T3 PL 06727008 T PL06727008 T PL 06727008T PL 06727008 T PL06727008 T PL 06727008T PL 1877098 T3 PL1877098 T3 PL 1877098T3
Authority
PL
Poland
Prior art keywords
carboxylesterase
hydrolysed
alpha
amino acid
acid ester
Prior art date
Application number
PL06727008T
Other languages
English (en)
Inventor
Alan Hornsby Davidson
Alan Hastings Drummond
Lindsey Ann Needham
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0509226A external-priority patent/GB0509226D0/en
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of PL1877098T3 publication Critical patent/PL1877098T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL06727008T 2005-05-05 2006-05-04 Koniugaty estru alfa-aminokwasu z lekiem ulegające hydrolizie z udziałem karboksyloesterazy PL1877098T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0509226A GB0509226D0 (en) 2005-05-05 2005-05-05 Enzyme and receptor modulation
US68054205P 2005-05-13 2005-05-13
EP06727008.2A EP1877098B1 (en) 2005-05-05 2006-05-04 Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase
PCT/GB2006/001635 WO2006117567A2 (en) 2005-05-05 2006-05-04 Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase

Publications (1)

Publication Number Publication Date
PL1877098T3 true PL1877098T3 (pl) 2013-09-30

Family

ID=36609807

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06727008T PL1877098T3 (pl) 2005-05-05 2006-05-04 Koniugaty estru alfa-aminokwasu z lekiem ulegające hydrolizie z udziałem karboksyloesterazy

Country Status (11)

Country Link
US (5) US20090215800A1 (pl)
EP (4) EP1964577B1 (pl)
JP (2) JP2008542196A (pl)
KR (1) KR101332904B1 (pl)
AU (1) AU2006243000B2 (pl)
BR (1) BRPI0610368A8 (pl)
CA (1) CA2607020C (pl)
IL (1) IL186091A0 (pl)
MX (1) MX2007013257A (pl)
PL (1) PL1877098T3 (pl)
WO (1) WO2006117567A2 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0509223D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Enzyme inhibitors
GB0608823D0 (en) * 2006-05-04 2006-06-14 Chroma Therapeutics Ltd Inhibitors of P13 kinase
GB0608822D0 (en) * 2006-05-04 2006-06-14 Chroma Therapeutics Ltd Inhibitors of DHFR
EP2013175B9 (en) * 2006-05-04 2020-11-11 Macrophage Pharma Limited p38 MAP KINASE INHIBITORS
GB0608837D0 (en) 2006-05-04 2006-06-14 Chroma Therapeutics Ltd Inhibitors of MAP kinase
GB0608821D0 (en) * 2006-05-04 2006-06-14 Chroma Therapeutics Ltd DHFR enzyme inhibitors
GB0608854D0 (en) * 2006-05-04 2006-06-14 Chroma Therapeutics Ltd P13 kinase inhibitors
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
WO2008053131A1 (en) * 2006-10-30 2008-05-08 Chroma Therapeutics Ltd. Hydroxamates as inhibitors of histone deacetylase
GB0622084D0 (en) 2006-11-06 2006-12-13 Chroma Therapeutics Ltd Inhibitors of HSP90
US20100267774A1 (en) * 2007-11-07 2010-10-21 Chroma Therapeutics Ltd. P38 map kinase inhibitors
GB0803747D0 (en) * 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
JP5555186B2 (ja) * 2008-02-29 2014-07-23 クロマ セラピューティクス リミテッド ｐ３８ＭＡＰキナーゼ阻害剤
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
WO2010144696A1 (en) 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
US9556426B2 (en) 2009-09-16 2017-01-31 Celgene Avilomics Research, Inc. Protein kinase conjugates and inhibitors
JP2013516422A (ja) 2009-12-30 2013-05-13 アビラ セラピューティクス， インコーポレイテッド タンパク質のリガンド−指向性共有的修飾
GB201009853D0 (en) 2010-06-11 2010-07-21 Chroma Therapeutics Ltd HSP90 inhibitors
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
PL3222616T3 (pl) 2012-10-17 2019-12-31 Macrophage Pharma Limited N-[2-{4-[6-amino-5-(2,4-difluorobenzoilo)-2-oksopirydyn-1(2h)-ylo]-3,5-difluorofenylo}etylo)-L-alaninian tert-butylu lub jego sól, hydrat lub solwat
GB201504694D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
WO2017216297A1 (en) 2016-06-16 2017-12-21 Glaxosmithkline Intellectual Property Development Limited Dosage regimen
US10256877B2 (en) * 2017-08-02 2019-04-09 Qualcomm Incorporated Apparatus and methods for beam refinement
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use
CN111303024B (zh) * 2018-12-12 2023-03-28 安徽中科拓苒药物科学研究有限公司 一种喹啉结构的pan-KIT激酶抑制剂及其用途
EP4687866A1 (en) 2023-04-02 2026-02-11 The Francis Crick Institute Limited Inhibitors of ets2-activating molecules for the treatment of inflammatory diseases

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1345502A (en) 1972-07-06 1974-01-30 Parke Davis & Co Quinazoline compounds and processes for their production
US4725687A (en) * 1986-04-28 1988-02-16 Southern Research Institute 5-methyl-5-deaza analogues of methotrexate and N10 -ethylaminopterin
US5175153A (en) * 1987-11-30 1992-12-29 Warner-Lambert Company Substituted alpha-amino acids having pharmaceutical activity
US5331006A (en) * 1990-08-31 1994-07-19 Warner-Lambert Company Amino acid analogs as CCK antagonists
AU666416B2 (en) * 1993-01-29 1996-02-08 Tanabe Seiyaku Co., Ltd. Ellipticine derivative and process for preparing the same
US5480906A (en) * 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
EP0860433B1 (en) * 1995-11-07 2002-07-03 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
PL352824A1 (pl) * 1999-04-09 2003-09-08 Abbott Gmbh & Co.Kg Proleki inhibitorów trombiny
US6448256B1 (en) * 1999-05-24 2002-09-10 University Of Massachusetts Antibiotic prodrugs
NZ517613A (en) * 1999-09-08 2004-01-30 Sloan Kettering Inst Cancer Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
WO2002039997A2 (en) * 2000-11-01 2002-05-23 Millennium Pharmaceuticals, Inc. Ace-2 modulating compounds and use thereof
PL372288A1 (pl) 2002-02-22 2005-07-11 Teva Pharmaceutical Industries Ltd. Sposób wytwarzania chlorku benzoizoksazolometanosulfonylu i jego amidowanie z wytworzeniem zonisamidu
AR038703A1 (es) * 2002-02-28 2005-01-26 Novartis Ag Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
CN101259120B (zh) * 2002-03-04 2012-07-04 Hdac默克研究有限责任公司 辛二酰苯胺异羟肟酸或其可药用盐在制备诱导末期分化的药物的用途
EP1487794A1 (en) 2002-03-14 2004-12-22 Bayer Aktiengesellschaft Monocyclic aroylpyridinones as antiinflammatory agents
JP2006512318A (ja) * 2002-11-12 2006-04-13 アルコン，インコーポレイテッド 眼の血管新生もしくは水腫状の疾患および障害を処置するためのヒストンデアセチラーゼインヒビター
AU2004289174B2 (en) * 2003-07-29 2011-05-19 Signature R&D Holdings, Lcc Amino acid prodrugs
WO2005037272A1 (en) * 2003-10-22 2005-04-28 Arpida A/S Benzimidazole derivatives and use thereof as peptide deformylase inhibitors
WO2005072061A2 (en) * 2004-02-02 2005-08-11 Biosight Ltd. Conjugates for cancer therapy and diagnosis
AU2005219859A1 (en) * 2004-02-27 2005-09-15 Schering Corporation Inhibitors of hepatitis C virus NS3 protease
CN101010298A (zh) * 2004-04-05 2007-08-01 默克Hdac研究有限责任公司 组蛋白脱乙酰酶抑制剂前药
AU2005243175B2 (en) * 2004-05-14 2011-12-01 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
GB0509225D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
GB0509223D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Enzyme inhibitors
GB0509224D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of intracellular enzymatic activity
GB0619753D0 (en) * 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
GB0621830D0 (en) * 2006-11-02 2006-12-13 Chroma Therapeutics Ltd Inhibitors of p38 mitogen-activated protein kinase

Also Published As

Publication number Publication date
EP1964578A3 (en) 2008-11-05
US20210361772A1 (en) 2021-11-25
KR101332904B1 (ko) 2013-11-26
AU2006243000B2 (en) 2011-05-26
EP1964577A3 (en) 2008-11-05
BRPI0610368A8 (pt) 2015-09-08
JP2013241423A (ja) 2013-12-05
KR20080003809A (ko) 2008-01-08
EP1877098B1 (en) 2013-04-24
CA2607020C (en) 2015-01-13
BRPI0610368A2 (pt) 2010-06-15
WO2006117567A2 (en) 2006-11-09
EP1964578A2 (en) 2008-09-03
AU2006243000A1 (en) 2006-11-09
US20190231887A1 (en) 2019-08-01
MX2007013257A (es) 2008-01-21
EP1964577B1 (en) 2016-04-13
EP3530290A1 (en) 2019-08-28
US20180000952A1 (en) 2018-01-04
CA2607020A1 (en) 2006-11-09
EP1964577A2 (en) 2008-09-03
JP2008542196A (ja) 2008-11-27
IL186091A0 (en) 2008-01-20
EP1877098A2 (en) 2008-01-16
US20090215800A1 (en) 2009-08-27
US20150126534A1 (en) 2015-05-07
WO2006117567A3 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
PL1877098T3 (pl) Koniugaty estru alfa-aminokwasu z lekiem ulegające hydrolizie z udziałem karboksyloesterazy
CY2018030I1 (el) Φαρμακοτεχνικη μορφη 514
PT2097111E (pt) Heterodímeros de ácido glutámico
NO20075628L (no) Farmasøytiske formuleringer
BRPI0820381A2 (pt) Formulações farmacêuticas
EP1953191A4 (en) polylactic acid
DK2068886T3 (da) Lipidholdige præparater
BRPI0715712A2 (pt) Composição farmacêutica
BRPI0817313A2 (pt) Derivados do ácido tetrâmico e tetrônico halogenoalcóxispirocíclicos
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
DK1991519T3 (da) Forgrenede carboxylsyrediestere
BRPI0920521A2 (pt) combinação farmacêutica
BRPI0913379A2 (pt) formulações farmacêuticas sólidas compreendendo bibw 2992
DK3492069T3 (da) Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid
BRPI0719393A2 (pt) Composição farmacêutica
DK2234994T3 (da) Fedtsyre-butylester-blandinger
EP2124556A4 (en) PHARMACEUTICAL COMPOSITIONS
BRPI0720234A2 (pt) Composição farmacêutica
BRPI0716445A2 (pt) composiÇço farmacÊutica
EP2275414A4 (en) Cyclopentylacrylic acid amide derivative
DK1957073T3 (da) Lægemiddel
BRPI0921254A2 (pt) acidos naftilacéticos
DE502007000476D1 (de) Verbundlenkerachse
DK2054074T3 (da) Modificeret erythropoietin
DK2271321T3 (da) Farmaceutisk sammensætning 271